Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PRODIGE 104 B: mFOLFIRINOX for GEM- Borderline Resectable Pancreatic Cancer
NCT07592819Phase 2Not yet recruiting
- Sponsor
- Institut Paoli-Calmettes
- Start
- May 2026
- Primary completion
- May 2030
- Modality
- DNA Intercalators/Alkylators, Orthosteric Ligands
01
Overview
A Phase 2 trial of fluorouracil, folinic acid, irinotecan, oxaliplatin in pancreatic ductal adenocarcinoma (PDAC), sponsored by Institut Paoli-Calmettes. Planned start May 2026; status: not yet recruiting.
02
Drugs
fluorouracilfolinic acidirinotecanoxaliplatin
03
Conditions
pancreatic ductal adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT07592819.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07592819.